KOD vs GMAB

Genmab A/S (GMAB) offers the better valuation at 17.

6x trailing P/E (23. 0x forward), making it the more compelling value choice. Analysts rate Kodiak Sciences Inc. (KOD) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kodiak Sciences Inc.

(KOD) delivered a total return of +115. 0%, compared to -27. 6% for Genmab A/S (GMAB). Over 10 years, the gap is even starker: KOD returned +1920% versus GMAB's +74. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Genmab A/S (GMAB) is the lower-risk stock at 0.

92β versus Kodiak Sciences Inc. 's 1. 67β — meaning KOD is approximately 82% more volatile than GMAB relative to the S&P 500. On balance sheet safety, Kodiak Sciences Inc. (KOD) carries a lower debt/equity ratio of 47% versus 93% for Genmab A/S — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Kodiak Sciences Inc.

grew EPS 32. 6% year-over-year, compared to -87. 3% for Genmab A/S. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Genmab A/S (GMAB) is the more profitable company, earning 25.

9% net margin versus 0. 0% for Kodiak Sciences Inc. — meaning it keeps 25. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMAB leads at 33. 6% versus 0. 0% for KOD. At the gross margin level — before operating expenses — GMAB leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for KOD: 48.

1% to $64. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kodiak Sciences Inc.

(KOD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1920% 10Y return). Both have compounded well over 10 years (KOD: +1920%, GMAB: +74. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: KOD is a small-cap quality compounder stock; GMAB is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.